Sign In

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

FDA Expands Early Breast Cancer Indication For Abemaciclib With Endocrine Therapy

Oncology Practice Insider

On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. Read more